Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety profile, including the maximum tolerated
dose (MTD), of ATI-1123 a liposomal formulation of docetaxel, in the treatment of cancer
patients with advanced solid tumors.